| Evelyn Yoh Bolt, MD | |
|
13654 Xavier Ln, Suite 201b, Broomfield, CO 80023-3606 | |
| (720) 279-9098 | |
| (720) 540-4250 |
| Full Name | Evelyn Yoh Bolt |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Sleep Medicine |
| Location | 13654 Xavier Ln, Broomfield, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003076159 | NPI | - | NPPES |
| 370941YWN5 | Other | CO | MEDICARE PTAN |
| Entity Name | Inpatient Services, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710999768 PECOS PAC ID: 5496651267 Enrollment ID: O20031211000419 |
News Archive
Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.
The Business Software Alliance (BSA), the voice of the world's commercial software industry, today announced a settlement with iCan Benefit Group of Boca Raton, FL. iCan Benefit paid $61,500 to BSA to settle claims that it had unlicensed copies of Adobe, Microsoft and Symantec software installed on its computers. As part of the settlement agreement, the company agreed to delete all unlicensed copies of software from its computers, acquire any licenses necessary to become compliant, and commit to implementing stronger software asset management (SAM) practices.
Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.
New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.
› Verified 6 days ago
| Entity Name | Rem Sleep Medicine P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649502295 PECOS PAC ID: 8325178775 Enrollment ID: O20100610000618 |
News Archive
Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.
The Business Software Alliance (BSA), the voice of the world's commercial software industry, today announced a settlement with iCan Benefit Group of Boca Raton, FL. iCan Benefit paid $61,500 to BSA to settle claims that it had unlicensed copies of Adobe, Microsoft and Symantec software installed on its computers. As part of the settlement agreement, the company agreed to delete all unlicensed copies of software from its computers, acquire any licenses necessary to become compliant, and commit to implementing stronger software asset management (SAM) practices.
Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.
New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Evelyn Yoh Bolt, MD 686 Rockridge Dr, Lafayette, CO 80026-8701 Ph: (773) 742-1899 | Evelyn Yoh Bolt, MD 13654 Xavier Ln, Suite 201b, Broomfield, CO 80023-3606 Ph: (720) 279-9098 |
News Archive
Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.
The Business Software Alliance (BSA), the voice of the world's commercial software industry, today announced a settlement with iCan Benefit Group of Boca Raton, FL. iCan Benefit paid $61,500 to BSA to settle claims that it had unlicensed copies of Adobe, Microsoft and Symantec software installed on its computers. As part of the settlement agreement, the company agreed to delete all unlicensed copies of software from its computers, acquire any licenses necessary to become compliant, and commit to implementing stronger software asset management (SAM) practices.
Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.
New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.
› Verified 6 days ago
Shiraz Moinuddin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2095 W 6th Ave Ste 106, Broomfield, CO 80020 Phone: 720-494-4700 Fax: 720-494-4706 | |
Sander H Orent, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 290 Nickel St, Broomfield, CO 80020 Phone: 303-460-9339 Fax: 303-447-7241 | |
Dr. Indira Mahalingam, M.D. Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 3940 Broadlands Ln, Broomfield, CO 80020 Phone: 303-460-1589 Fax: 303-466-0533 | |
Louise E. Benson, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3308 W 11th Avenue Pl, Broomfield, CO 80020 Phone: 303-439-2259 Fax: 303-469-9331 | |
Dr. James Joseph Marr Jr., MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 14885 Irving St, Broomfield, CO 80023 Phone: 970-215-5700 | |
Tyler Gallegos, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 10526 Pierson Cir, Broomfield, CO 80021 Phone: 303-507-7256 |